Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Home CompaniesCogstate Ltd

Cogstate Ltd

Healthcare Health Information Services
PortfolioPortfolio WatchlistWatchlist
Company price
3.31 AUD -0.06 ( 1.78%)
Last update at 2026-09-28T06:10:00Z
VOLUME
259372
Market Cap
557.24M
P/E
36.00

Momentum Score

…

Cogstate Limited, a neuroscience solutions company, engages in the creation, validation, and commercialization of digital brain health assessments worldwide. The company offers digital cognitive assessment, endpoint data quality (rater services), remote assessment, scientific consulting, healthcare cognitive screening, and research and academic collaboration solutions for various therapeutic areas, including Alzheimer's disease and dementia, preclinical Alzheimer's disease, pediatrics and rare disease, Parkinson's disease, multiple sclerosis, schizophrenia, oncology, safety, and sleep and mood disorders. It also designs and provides quality assurance services in clinical trials focused on the administration, scoring, and recording of conventional brain health assessments. In addition, it develops a tool for primary care physicians and/or hospitals to assess cognitive decline. Its technology and associated services are used to quantify the effect of disease and drugs, devices, or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The company serves biopharmaceutical companies, academic institutions, physicians, and patients. Cogstate Limited was incorporated in 1999 and is based in Melbourne, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.30
Low
3.39
High
52 Week Price Range
1.73
Low
3.50
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Cogstate Ltd develops and delivers computerized cognitive assessment tools and clinical-trial services used to measure brain function in neurology, oncology and psychiatry studies. Long-term growth may be driven by rising demand for validated digital cognitive endpoints in Alzheimer's and other CNS trials, an aging population, and broader adoption of remote and biomarker-enabled trial designs. Investors may find the company attractive because it appears positioned with regulatory-recognized tests, recurring service revenues from pharmaceutical clients, and scalable data assets supporting long-term contracts.

Primary investment risks include sensitivity to pharmaceutical R&D cycles and customer concentration, competition from other digital-assessment providers, and regulatory and data-privacy compliance demands that could increase costs or slow adoption.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
3.37
Dividend Yield
0.91%
Revenue TTM
60.86M
Revenue Per Share
0.36
Gross Profit TTM
35.02M
Debt / Equity
0.01
ROE
22.48%
Net Debt
-34.41M
ROCE
20.14%
Diluted EPS TTM
0.09

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax 16.47M 13.91M 10.65M 3.03M 10.69M
Net income 12.16M 10.14M 5.45M 3.57M 7.52M
Selling general administrative 12.90M 12.82M 13.61M 14.41M 11.80M
Selling and marketing expenses - 0.04M 0.02M 0.07M 0.04M
Gross profit 20.24M 30.69M 37.60M 21.59M 26.68M
Reconciled depreciation 3.09M 2.95M 2.74M 2.59M 2.32M
Ebit 12.35M 13.98M 7.16M 3.09M 10.78M
Ebitda 15.51M 16.93M 9.90M 5.69M 13.11M
Depreciation and amortization 3.16M 2.95M 2.74M 2.59M 2.32M
Operating income 12.35M 10.80M 6.17M 3.44M 15.85M
Other operating expenses 47.52M 40.02M 64.12M 2.33M 4.55M
Interest expense 0.02M 0.08M 0.05M 0.07M 0.09M
Tax provision 4.22M 3.76M 1.65M -0.54M 3.17M
Interest income 0.88M 0.93M - 0.70M 0.05M
Net interest income 0.86M 0.85M -0.05M 0.63M -0.04M
Income tax expense 4.31M 3.76M 2.48M -0.54M 3.17M
Total revenue 59.87M 50.81M 66.27M 40.45M 44.98M
Total operating expenses 7.89M 19.89M 18.53M 19.34M 15.82M
Cost of revenue 39.63M 20.12M 28.67M 18.86M 18.30M
Total other income expense net 4.11M 3.11M 4.47M 0.14M -0.13M
Net income from continuing ops 11.90M 10.14M 5.45M 3.57M 7.52M
Net income applicable to common shares - 10.14M 5.45M 3.57M 7.52M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 78.03M 64.77M 86.60M 54.07M 58.45M
Intangible assets 14.07M 10.81M 10.48M 11.11M 10.77M
Other current assets 1.78M 0.53M 1.62M 1.22M 2.08M
Total liab 19.78M 16.88M 25.33M 16.38M 25.52M
Total stockholder equity 58.25M 47.90M 61.27M 37.69M 32.92M
Other current liab 10.18M - 12.59M 6.74M 12.03M
Common stock 39.78M - 54.76M 36.32M 36.15M
Capital stock 39.79M 37.76M 36.57M 36.32M 36.15M
Retained earnings 25.28M 5.76M 3.50M -0.16M -3.25M
Other liab - - - - 6.67M
Other assets - - - 3.58M 3.66M
Cash 34.77M 35.56M 45.11M 28.68M 30.60M
Cash and equivalents - - - 20.19M 18.19M
Total current liabilities 16.67M 13.34M 18.84M 12.17M 18.26M
Current deferred revenue 5.30M - 5.63M 5.01M 4.64M
Net debt -34.41M - -44.10M -28.41M -29.37M
Short term debt 0.12M - 0.33M 0.24M 0.64M
Short long term debt - - 0.11M 0.12M 0.18M
Short long term debt total 0.36M - 1.01M 0.26M 1.23M
Other stockholder equity - - 0.00M -54.28M -47.64M
Property plant equipment - - - 0.60M 2.02M
Total current assets 58.99M 50.30M 65.08M 38.78M 42.00M
Net tangible assets - - - - 22.16M
Net receivables 22.44M 12.81M 18.35M 7.63M 8.32M
Inventory - - 0.00M 1.25M 1.01M
Accounts payable 1.08M 1.52M 0.30M 0.19M 0.95M
Accumulated other comprehensive income -6.81M - 3.01M 1.53M 0.03M
Non currrent assets other - - 15.69M -17.58M -18.52M
Non current assets total 19.04M 14.47M 21.52M 15.28M 16.45M
Capital lease obligations 0.36M 0.47M 0.56M 0.26M 1.23M
Long term debt total - - - 0.03M 0.59M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -2.24M -1.12M -1.68M -3.53M
Change to liabilities - - - 0.00M -2.13M
Total cashflows from investing activities -6.45M -2.24M -1.68M -1.68M -3.53M
Net borrowings - - - - -0.65M
Total cash from financing activities -4.04M -3.79M -4.91M -0.89M 0.76M
Change to operating activities - - - - -0.64M
Net income 12.16M 10.14M 8.32M 5.36M 10.89M
Change in cash -2.81M 5.44M 2.11M -1.92M 6.96M
Begin period cash flow 37.58M 30.12M 28.68M 30.60M 23.64M
End period cash flow 34.77M 35.56M 30.12M 28.68M 30.60M
Total cash from operating activities 9.69M 11.48M 8.67M 0.98M 14.09M
Issuance of capital stock 1.44M 1.15M 0.62M 0.18M 1.41M
Depreciation 3.16M - 4.18M 1.30M 1.78M
Other cashflows from investing activities - -1.95M -1.00M 0.53M 0.03M
Dividends paid 2.30M - - - 1.08M
Change to account receivables -7.78M -4.17M -3.71M 0.82M -0.33M
Sale purchase of stock -3.10M -4.84M -3.59M -0.57M -0.57M
Other cashflows from financing activities -0.11M -0.11M -1.95M -0.51M -3.53M
Change to netincome - - - 1.06M 2.32M
Capital expenditures 0.53M 3.07M 2.88M 2.21M 3.56M
Change in working capital -7.79M -1.42M -4.42M 0.82M -0.33M
Stock based compensation - - 1.12M 2.38M 3.20M
Other non cash items 2.17M 12.90M 13.10M -5.67M 1.41M
Free cash flow 9.17M 8.40M 7.12M -1.23M 10.53M

Peer Comparison*

Sector: Healthcare Industry: Health Information Services

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CGS
Cogstate Ltd		 -0.06
1.78%		 3.31 36.00 28.17 9.16 6.93 6.33 19.23
PME
Pro Medicus Ltd		 1.15
0.71%		 162.15 64.69 89.29 65.34 37.37 63.47 81.35
AYA
ARTRYA Ltd		 -0.24
6.30%		 3.57 - - 23230.33 8.10 20004.93 0.33
EIQ
Echoiq Ltd		 -0.05
8.47%		 0.54 - - 5395.50 40.77 5059.22 -8.27
ALC
Alcidion Group Ltd		 -
-%		 0.10 - 1.23 2.68 1.49 2.75 18.06

Profile*

Cogstate Ltd

Cogstate Limited, a neuroscience solutions company, engages in the creation, validation, and commercialization of digital brain health assessments worldwide. The company offers digital cognitive assessment, endpoint data quality (rater services), remote assessment, scientific consulting, healthcare cognitive screening, and research and academic collaboration solutions for various therapeutic areas, including Alzheimer's disease and dementia, preclinical Alzheimer's disease, pediatrics and rare disease, Parkinson's disease, multiple sclerosis, schizophrenia, oncology, safety, and sleep and mood disorders. It also designs and provides quality assurance services in clinical trials focused on the administration, scoring, and recording of conventional brain health assessments. In addition, it develops a tool for primary care physicians and/or hospitals to assess cognitive decline. Its technology and associated services are used to quantify the effect of disease and drugs, devices, or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The company serves biopharmaceutical companies, academic institutions, physicians, and patients. Cogstate Limited was incorporated in 1999 and is based in Melbourne, Australia.

367 Collins Street, Melbourne, VIC, Australia, 3000

61 3 9664 1300

https://www.cogstate.com

160

Name Title Year Born
Mr. Bradley John O'Connor B.Bus, C.A., CA CEO, MD & Exec. Director NA
Prof. Paul Maruff BBSc (Hons), Ph.D. Founder & Chief Innovation Officer NA
Mr. Darren Watson Chief Financial Officer NA
Mr. Benjamin Bloomfield Chief Technology Officer NA
Mr. Kenneth Billard Chief Commercial Officer NA
Dr. Chris Edgar Ph.D. Chief Science Officer NA
Ms. Rachel Colite VP of Strategic Initiatives, Communication & People NA
Mr. David James Franks B.Ec, BEc, C.A., CA, F Fin, J.P., JP. Company Sec. 1970
Dr. Amy E. Veroff Ph.D. Principal Consultant NA
Mr. Bradley John O'Connor B.Bus, C.A., CA CEO, MD & Executive Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ATM
AUD 1.06
+8.67%
G6M
AUD 3.49
+7.06%
NST
AUD 23.47
+6.15%
INA
AUD 4.76
+5.78%
MEZ
AUD 4.53
+5.35%
KAR
AUD 1.55
-12.89%
NMG
AUD 0.07
-12.66%
MI6
AUD 0.84
-10.64%
BRE
AUD 3.56
-9.64%
CXO
AUD 0.32
-8.70%

Equity Sectors*

  • Basic Materials

    -2.53%

  • Communication Services

    -0.20%

  • Consumer Cyclical

    -0.30%

  • Consumer Defensive

    -0.14%

  • Energy

    -1.70%

  • Financial Services

    -0.11%

  • Healthcare

    -0.80%

  • Industrials

    -0.68%

  • Real Estate

    +0.72%

  • Technology

    -0.78%

  • Utilities

    +2.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…